Dry Granulation Excipient Market Trends

Growth Drivers

• Rising Healthcare Expenditure: Healthcare costs are rising at an exceptional rate due to factors like the high cost of treatment, increasing drug prices, and growth in medical enrollment which has increased the need for highly efficient and low-cost drugs in the market. Increased expenditure allows producers of excipients to fund research and development initiatives to create novel excipients suited to particular needs of the dry granulation procedure for creating affordable drugs in the market. According to research, in 2021 the global healthcare expenditure was 9.7% of the global GDP.
• Technological Advancements in Drug Manufacturing: Technological advancements in dry granulation techniques, such as roller compaction involves compacting dry powders between two rollers to form a dense sheet, which is then milled into granules. This process offers advantages such as increased uniformity of granule size and improved flow properties, resulting in more consistent drug delivery.   and slugging which involves compressing powder blends into large tablets or "slugs," which are then broken down into granules. Slugging offers advantages such as simplicity and scalability, making it suitable for both small-scale and large-scale production. These innovations are enhancing the efficiency and effectiveness of drug formulation processes, leading to the expansion of dry granulation excipients.
• Improved Access to Healthcare: Enhanced healthcare access drives a surge in demand for pharmaceuticals. As more individuals obtain vital medications, the need for pharmaceuticals rises. This increased demand extends to solid oral dosage forms, which rely on specific dry granulation excipients. Consequently, there is an expansion in the market for pharmaceutical manufacturers, resulting in a rise in the demand for excipients crucial in producing tablets and capsules.

Challenges

• Delay in Approval: New excipient approval processes can be drawn out, costly, and complicated. Pharmaceutical businesses may find it more difficult to justify their investment in developing new medicines due to the high capital costs involved and the potential for further delays in the time to market for novel excipients. Furthermore, the FDA and other regulatory bodies must approve new excipients before they may be used in pharmaceutical products. Thus, negatively affecting the market expansion
• Lengthy manufacturing process due to the production of excipients in large quantities to meet the needs of the pharmaceutical industry is expected to hinder market growth.
• Several technical issues regarding the process of dry granulation can also impede the market growth in the forecast period.